National Midterm Outcomes of Transcatheter Aortic Valve Implantation vs Surgical Aortic Valve Replacement

经导管主动脉瓣植入术与外科主动脉瓣置换术的全国中期结果

阅读:1

Abstract

BACKGROUND: This study compared the early and midterm outcomes of transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) in a real-world entire population in Korea. METHODS: During 5 years from June 2015 to May 2019, 1468 patients underwent primary isolated transfemoral TAVI and 3897 patients underwent primary isolated SAVR in Korea. Early and midterm clinical outcomes were compared between the groups, and propensity score-matched analysis was also performed to balance between the groups. Subgroup analyses were performed by dividing the overall cohort into 6 age-subgroups of <65, 65 to 69, 70 to 74, 75 to 79, 80 to 84, and ≥85 years. Follow-up was 100% complete. Median follow-up duration was 2.5 years in the TAVI group and 3.0 years in the SAVR group. RESULTS: There was no difference in periprocedural mortality between the groups in the overall cohort (3.2% in TAVI vs 3.5% in SAVR, P =.66), whereas SAVR demonstrated higher periprocedural mortality in the matched cohort (2.9% in TAVI vs 5.6% in SAVR, P =.003). Cumulative incidence of all-cause mortality was not significantly different between TAVI and SAVR in the matched cohort (hazard ratio, 0.96; 95% CI, 0.79-1.16; P =.64), and was also not significantly different in every matched age-subgroup. Other midterm clinical outcomes, including stroke, endocarditis, and reintervention, were comparable between the groups, whereas the cumulative incidence of permanent pacemaker implantation was significantly higher in TAVI. CONCLUSIONS: TAVI and SAVR demonstrated comparable midterm survival in the real-world entire population from 2015 to 2019 in Korea. Comparable midterm survival was also demonstrated between all age-subgroups.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。